Milrinone: Difference between revisions
(Created page with "==General== *Type: Vasopressors *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug Ratings in Pregnancy|Pregnanc...") |
No edit summary |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Dosing=== | |||
*Normal renal function: | |||
0.25 - 0.75 mcg/kg/min | |||
*Creatinine clearance < 50mL/min, reduce infusion rate | |||
===Rate of Titration=== | |||
*Q2H; slower titration rate if renal insufficiency | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 22: | Line 28: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
*Tachyarrhythmias | |||
*Hypotension | |||
*Myocardial ischemia | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 31: | Line 37: | ||
*Excretion: | *Excretion: | ||
*Mechanism of Action: | *Mechanism of Action: | ||
===Primary Receptor=== | |||
*PDE-3 inhibitor | |||
===Relative Effects=== | |||
*↑HR | |||
*↑↑↑SV | |||
*↓SVR | |||
==Notes== | |||
*Can use as alternative to dobutamine in pts with cardiogenic shock and on b-blockers | |||
*Causes pulmonary vasodilation, may be good choice in pts with RV failure | |||
*↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR | |||
*Use with caution in pt with renal failure and hypovolemia | |||
===Indication=== | |||
low cardiac output states due to impaired myocardial contractility | |||
==See Also== | ==See Also== | ||
Revision as of 14:31, 20 December 2014
General
- Type: Vasopressors
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Dosing
- Normal renal function:
0.25 - 0.75 mcg/kg/min
- Creatinine clearance < 50mL/min, reduce infusion rate
Rate of Titration
- Q2H; slower titration rate if renal insufficiency
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Tachyarrhythmias
- Hypotension
- Myocardial ischemia
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Primary Receptor
- PDE-3 inhibitor
Relative Effects
- ↑HR
- ↑↑↑SV
- ↓SVR
Notes
- Can use as alternative to dobutamine in pts with cardiogenic shock and on b-blockers
- Causes pulmonary vasodilation, may be good choice in pts with RV failure
- ↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR
- Use with caution in pt with renal failure and hypovolemia
Indication
low cardiac output states due to impaired myocardial contractility